Singh Tarvinder P, Weinstein Jonathan R, Murphy Sean P
Departments of Neurology, University of Washington School of Medicine, Seattle, WA, 98195, USA.
Neurological Surgery, University of Washington School of Medicine, Seattle, WA, 98195, USA.
Adv Neurobiol. 2017;15:281-293. doi: 10.1007/978-3-319-57193-5_10.
Tissue plasminogen activator (tPA) was first approved in the USA 25 years ago for those who had experienced a recent occlusion (<3 h) of a cerebral vessel. Now, advances in clot retrieval (stentriever), in concert with tPA, heralds new optimism for ischemic stroke victims, but adds more pressure to identify therapies that will minimize hypoxic damage, protect compromised cells, and promote rehabilitation. In the past preclinical investigations have been poor at predicting potential clinical therapy, but they have contributed enormously to understanding post-stroke pathology. Current clinical trials ( www.strokecenter.org/trials ) anticipate a broad range of approaches: from hypothermia, to cell therapy, to neuroprotection.
组织型纤溶酶原激活剂（tPA）于25年前在美国首次获批用于近期发生脑血管闭塞（<3小时）的患者。如今，血栓清除术（取栓支架）与tPA协同发展，为缺血性中风患者带来了新的希望，但也增加了确定能将缺氧损伤降至最低、保护受损细胞并促进康复的治疗方法的压力。过去，临床前研究在预测潜在临床治疗方面表现不佳，但它们对理解中风后病理过程做出了巨大贡献。当前的临床试验（www.strokecenter.org/trials）预计会有广泛的方法：从低温疗法到细胞疗法，再到神经保护。
